Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women.
Anti-Mullerian hormone (AMG) reduction in women with hyperinsulinemia in therapy with metformin suggests that metformin affects the level of AMH and ovulatory dysfunction through insulin-mediated mechanisms. Aim of the study was to assess the effects of metformin hydrochloride (Siofor) on the level of AMH in women with polycystic ovary syndrome and obesity. The study involved 40 women with PCOS, aged 22 to 35 years (mean age 28.7±5.2 years) with body mass index (BMI) 32.5±4.3 kg/m2. All patients received metformin hydrochloride (Siofor) orally, 1 tablet (850 mg) two times a day for six months. After three and six months of therapy anthropometric characteristics, concentration of hormones in the blood serum were assessed. In patients receiving Siofor a decrease of BMI, waist-hip ratio (P<0.05), concentration of T, as well as free androgen index (FAI) (P<0.01) was shown. Furthermore, there was a decrease in ovarian volume by 12%. AMH concentration during therapy did not changed significantly. The hypothesis that a decline in AMG level is a consequence of the reduced BMI, which was significant in the group of women with hyperinsulinemia, does not seem convincing in view of the fact that patients with a normal insulin level also showed a trend to lower BMI, which, however, was not accompanied by a decrease in its concentration.